Zobrazeno 1 - 10
of 315
pro vyhledávání: '"Kelly A Johnson"'
Autor:
Jaime R Barrett, Gabriel K Innes, Kelly A Johnson, Guillaume Lhermie, Renata Ivanek, Amelia Greiner Safi, David Lansing
Publikováno v:
PLoS ONE, Vol 17, Iss 6, p e0270442 (2022)
[This corrects the article DOI: 10.1371/journal.pone.0261010.].
Externí odkaz:
https://doaj.org/article/6ea0a73c84cb41efbd435bbb86ed55a4
Autor:
Jaime R Barrett, Gabriel K Innes, Kelly A Johnson, Guillaume Lhermie, Renata Ivanek, Amelia Greiner Safi, David Lansing
Publikováno v:
PLoS ONE, Vol 16, Iss 12, p e0261010 (2021)
Antimicrobial use in animal agriculture is often perceived to play a role in the emerging threat of antimicrobial resistance. Increased consumer awareness of this issue places pressure on animal husbandry to adopt policies to reduce or eliminate anti
Externí odkaz:
https://doaj.org/article/77e93afb9fdc4a46ae34d7d9a5cfd200
Autor:
Elmira Flem, Celine Mouawad, Arto A. Palmu, Heather Platt, Kelly D. Johnson, E. David McIntosh, Jacobo Abadi, Ulrike K. Buchwald, Kristen Feemster
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 997-1010 (2024)
Introduction Infant immunization programs using pneumococcal conjugate vaccines (PCVs) have reduced the rates of pneumococcal disease through direct vaccine-induced protection in vaccinated children and through indirect protection in non-vaccinated c
Externí odkaz:
https://doaj.org/article/5fc4834eb542452fa1ce111541ca8cee
Autor:
Salini Mohanty, Jui-Hua Tsai, Ning Ning, Ana Martinez, Rishi P. Verma, Bianca Chun, Kelly D. Johnson, Nicole Cossrow, M. Doyinsola Bailey, Thomas Weiss, Elmira Flem, Jordana K. Schmier
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 966-973 (2024)
Objectives It is important to assess healthcare providers (HCPs) knowledge, attitudes, perceptions, and preferences towards new pneumococcal vaccines for adults.Methods HCPs who met eligibility criteria completed an online survey between March – Ma
Externí odkaz:
https://doaj.org/article/c1780d314f504aaa9d00291946954888
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 7, Pp 1501-1514 (2024)
Abstract Introduction This study aimed to estimate and compare the lifetime clinical and economic burden of invasive pneumococcal diseases (IPD) attributable to the serotypes contained in a new 21-valent pneumococcal conjugate vaccine (V116) vs. the
Externí odkaz:
https://doaj.org/article/82d50dc31ce148ba9956e41c49f62dbc
Publikováno v:
Expert Review of Vaccines, Vol 22, Iss 1, Pp 596-607 (2023)
Background Adults with chronic or immunocompromising conditions have an elevated risk of invasive pneumococcal disease, yet their pneumococcal vaccination rates remain low. Methods This retrospective cohort study used the IBM MarketScan® Multi-State
Externí odkaz:
https://doaj.org/article/19ee6122ef044e248e8c5440d0a922ed
Publikováno v:
Frontiers in Nutrition, Vol 10 (2023)
Externí odkaz:
https://doaj.org/article/be167e9e90e448429656340c9e4c368b
Autor:
Arijita Deb, Bélène Podmore, Rosemarie Barnett, Dominik Beier, Wolfgang Galetzka, Nawab Qizilbash, Dennis Haeckl, Timo Boellinger, Kelly D. Johnson, Thomas Weiss
Publikováno v:
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Despite recommendations from the German Standing Committee on Vaccination (STIKO), pneumococcal vaccination coverage remains low in vulnerable populations. This study estimated the pneumococcal vaccination coverage rate (VCR) and
Externí odkaz:
https://doaj.org/article/9c65cf8423474b60bd31244606b1aaf0
Autor:
Natalie Zarabi, Martina Aldvén, Sigrid Sjölander, Hanna Fues Wahl, Goran Bencina, Kelly D Johnson, Sven-Arne Silfverdal
Publikováno v:
PLoS ONE, Vol 18, Iss 7, p e0287581 (2023)
Pneumococcal disease is a major cause of clinical and economic burden worldwide. This study investigated the burden of pneumococcal disease in Swedish adults. A retrospective population-based study was conducted using Swedish national registers, incl
Externí odkaz:
https://doaj.org/article/e68a53fc632f41f599ce1710b9dbb678
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 1 (2023)
The Centers for Disease Control recommends pneumococcal vaccination for U.S. adults aged 19–64 years with chronic or immunocompromising conditions, however, vaccination coverage is low and regional variations in coverage are rarely studied. This st
Externí odkaz:
https://doaj.org/article/f1a1155a75b640faac6e31b3831c5674